Taofeek Owonikoko
University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center

Last Updated On 1/8/2024 3:00:44 PM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.

Employment
No Relationships to Disclose

Leadership
No Relationships to Disclose

Stock and Other Ownership Interests
Company: Cambium Oncology
Recipient: You
Company: Taobob LLC
Recipient: You
Company: GenCart
Recipient: You
Company: Coherus Biosciences
Recipient: You

Honoraria
No Relationships to Disclose

Consulting or Advisory Role
Company: Novartis
Recipient: You
Company: Celgene
Recipient: You
Company: Abbvie
Recipient: You
Company: Eisai
Recipient: You
Company: G1 Therapeutics
Recipient: You
Company: Takeda
Recipient: You
Company: Bristol-Myers Squibb
Recipient: You
Company: MedImmune
Recipient: You
Company: BerGenBio
Recipient: You
Company: Lilly
Recipient: You
Company: Amgen
Recipient: You
Company: AstraZeneca
Recipient: You
Company: PharmaMar
Recipient: You
Company: Boehringer Ingelheim
Recipient: You
Company: EMD Serono
Recipient: You
Company: Bayer
Recipient: You
Company: Merck
Recipient: You
Company: Jazz Pharmaceuticals
Recipient: You
Company: Ipsen
Recipient: You
Company: Eisai
Recipient: You
Company: Roche/Genentech
Recipient: You
Company: Janssen
Recipient: You
Company: Exelixis
Recipient: You
Company: BeiGene
Recipient: You
Company: Triptych Health Partners
Recipient: You
Company: Daichi
Recipient: You
Company: Coherus Biosciences
Recipient: You
Company: Heat Biologics
Recipient: You
Company: PUMA
Recipient: You
Company: Xcovery
Recipient: You
Company: Meryx
Recipient: You

Speakers' Bureau
No Relationships to Disclose

Research Funding
Company: Corvus Pharmaceuticals
Recipient: You
Company: Novartis
Recipient: Your Institution
Company: Bayer
Recipient: Your Institution
Company: Regeneron
Recipient: Your Institution
Company: AstraZeneca/MedImmune
Recipient: Your Institution
Company: Abbvie
Recipient: Your Institution
Company: G1 Therapeutics
Recipient: Your Institution
Company: Bristol-Myers Squibb
Recipient: Your Institution
Company: Amgen
Recipient: Your Institution
Company: Loxo/Lilly
Recipient: Your Institution
Company: Pfizer
Recipient: Your Institution
Company: Incyte
Recipient: Your Institution
Company: Merck
Recipient: Your Institution
Company: Oncorus
Recipient: Your Institution
Company: GlaxoSmithKline
Recipient: Your Institution
Company: Calithera Biosciences
Recipient: Your Institution
Company: Roche/Genentech
Recipient: Your Institution
Company: Meryx
Recipient: Your Institution
Company: Boehringer Ingelheim
Recipient: Your Institution
Company: Boehringer Ingelheim
Recipient: Your Institution
Company: Bayer
Recipient: Your Institution

Patents, Royalties, Other Intellectual Property
Please describe: OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3
Recipient: Your Institution
Please describe: SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO
Recipient: Your Institution
Please describe: DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor)
Recipient: Your Institution
Please describe: Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor)
Recipient: Your Institution

Expert Testimony
No Relationships to Disclose

Travel, Accommodations, Expenses
Company: AstraZeneca
Recipient: You
Company: Janssen
Recipient: You

Other Relationship
Company: Roche/Genentech
Recipient: You
Company: EMD Serono
Recipient: You
Company: Novartis
Recipient: You

(OPTIONAL) Uncompensated Relationships
Company: Reflexion Medical
Recipient: You

(OPTIONAL) Open Payments Link
Open Payments URL: https://openpaymentsdata.cms.gov/physician/253457